Fig. 1From: A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancerFlow diagram of this parallel randomised trial. EGFR: epidermal growth factor receptor; PFS: progression-free survival; TTP: time to progression; ORR: overall response rate; DCR: disease control rate; OS: overall survivalBack to article page